JAGUAR HEALTH, INC. Operating Lease, Weighted Average Discount Rate, Percent
JAGUAR HEALTH, INC. (JAGX) had Operating Lease, Weighted Average Discount Rate, Percent of 23.71% as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-19
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 23.71%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 23.36%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 24.48%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 24.07%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 23.71% 10-Q · filed 2026-08-19 | |
| 2026-03-31 | 23.36% 10-Q · filed 2026-05-20 | |
| 2025-12-31 | 24.48% 10-Q · filed 2026-08-19 | |
| 2025-09-30 | 24.07% 10-Q · filed 2025-11-14 | |
| 2025-06-30 | 23.61% 10-Q · filed 2025-08-14 | |
| 2025-03-31 | 20.03% 10-Q · filed 2025-05-15 | |
| 2024-12-31 | 20.75% 10-K · filed 2026-04-07 | |
| 2024-09-30 | 20.03% 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 20.03% 10-Q · filed 2024-08-13 | |
| 2024-03-31 | 19.74% 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 21.34% 10-K · filed 2025-03-31 | 16.82% 10-K · filed 2024-04-01 |
| 2023-09-30 | 16.82% 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 16.85% 10-Q · filed 2023-08-14 | |
| 2023-03-31 | 17.82% 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 17.89% 10-K · filed 2024-04-01 | |
| 2022-09-30 | 18.52% 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 18.46% 10-Q · filed 2022-08-22 | |
| 2022-03-31 | 21.80% 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 21.10% 10-K · filed 2023-03-24 | |
| 2021-09-30 | 21.10% 10-Q · filed 2021-11-17 | |
| 2021-06-30 | 21.10% 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |